Your browser doesn't support javascript.
loading
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross, Darren A E; Ashton, Susan E; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A; Spitzler, Paula J; Orme, Jonathon P; Finlay, M Raymond V; Ward, Richard A; Mellor, Martine J; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N; Red Brewer, Monica; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H P; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R; Pao, William.
  • Cross DA; Oncology Innovative Medicines and Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu.
  • Ashton SE; Oncology Innovative Medicines and.
  • Ghiorghiu S; Oncology Innovative Medicines and.
  • Eberlein C; Oncology Innovative Medicines and.
  • Nebhan CA; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Spitzler PJ; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Orme JP; Discovery Sciences, AstraZeneca, Macclesfield Cheshire;
  • Finlay MR; Oncology Innovative Medicines and.
  • Ward RA; Oncology Innovative Medicines and.
  • Mellor MJ; Oncology Innovative Medicines and.
  • Hughes G; Oncology Innovative Medicines and.
  • Rahi A; Oncology Innovative Medicines and.
  • Jacobs VN; Oncology Innovative Medicines and.
  • Red Brewer M; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Ichihara E; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Sun J; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Jin H; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • Ballard P; Oncology Innovative Medicines and.
  • Al-Kadhimi K; Oncology Innovative Medicines and.
  • Rowlinson R; Oncology Innovative Medicines and.
  • Klinowska T; Oncology Innovative Medicines and.
  • Richmond GH; Oncology Innovative Medicines and.
  • Cantarini M; Oncology Innovative Medicines and.
  • Kim DW; Seoul National University Hospital, Seoul, Republic of Korea.
  • Ranson MR; University of Manchester, Christie Hospital, Manchester, United Kingdom;
  • Pao W; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu.
Cancer Discov ; 4(9): 1046-61, 2014 Sep.
Article en En | MEDLINE | ID: mdl-24893891
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Acrilamidas / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Receptores ErbB / Compuestos de Anilina / Neoplasias Pulmonares / Mutación / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Acrilamidas / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Receptores ErbB / Compuestos de Anilina / Neoplasias Pulmonares / Mutación / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article